BWX Technologies

BWX Technologies manufactures nuclear components for the US Navy (submarine/carrier reactors), produces TRISO fuel and enriched uranium for the DoE/NNSA, and is expanding into commercial nuclear manufacturing via the PCG acquisition.

BWX Technologies manufactures naval nuclear reactor components (sole-source to the U.S. Navy), fabricates TRISO fuel, and — via its BANR microreactor — is now a U.S. Army-selected vendor for deployable nuclear power. On Aug 3, 2026 BWXT announced it is divesting its medical isotopes business to concentrate capital on nuclear national security + commercial nuclear power.

• monetization model: Contract-based one-time hardware + recurring nuclear fuel/services + medical isotopes; cost-plus, fixed-price, and T&M contracts. (FY2024 10-K, Item 1 Business, sec.gov ; Acc. 0001486957-25-000008)
• revenue mix: ~86% Government Operations, ~14% Commercial Operations. (FY2024 10-K, Note 21 Segment Reporting; same URL; Acc. 0001486957-25-000008)
• who pays: U.S. federal government (U.S. Navy, DOE/NNSA), commercial nuclear utilities, medical isotope/radiopharma buyers. (FY2024 10-K, Item 1 Business/Customer Concentrations; same URL; Acc. 0001486957-25-000008)
• margin_value_capture: FY2024 operating margin ~14%; value accrues in Government Operations sole-source nuclear components/fuel/services. (FY2024 10-K, Consolidated Statements of Income; same URL; Acc. 0001486957-25-000008)

• customer classes: Government - Program Buyers (U.S. Navy, DOE/NNSA), US Nuclear Utilities, Canadian nuclear utilities, medical isotope/radiopharma buyers. (FY2024 10-K, Item 1 Business/Customer Concentrations; same URL; Acc. 0001486957-25-000008)

BWXT monetizes through long-term contracts rather than one-off product sales. The FY2023 10-K describes contract types such as cost-reimbursable and fixed-price arrangements. The government segment is heavily dependent on U.S. government appropriations and multi-year defense programs.

Source: BWXT FY2023 10-K, Management’s Discussion and Analysis and Notes, CY2023, CIK 0001486957. Locator as above. Specific contract type percentages: needs primary source validation.

This qualitative claim is [SINGLE-SOURCE] if no independent contract-level filing is cited.

The commercial segment is more order-driven and fixed-price. For example, CANDU fuel fabrication is a made-to-order manufacturing business; medical isotope generators are shipped to radiopharmacies and distributors.

Q1 2026 revenues $860.2M (+14% YoY); FY26 guidance: Adj. EBITDA $650M–$665M, non-GAAP EPS $4.60–$4.75, FCF $315M–$330M; Q1 26 OCF $92.6M (+83% YoY); Government Operations $577.9M, Commercial Power $154.5M, Nuclear Medicine $127.8M

Q2 FY2026 revenue $901.6M (+18% YoY); Government Operations $601.3M (+2% YoY), Commercial Operations $302.5M (+72% YoY). FY2026 guidance RAISED to revenue $3,800M, adj. EBITDA $662–672M, non-GAAP EPS $4.70–4.80, FCF $345–360M [8-K EX-99.1, filed 2026-08-03].

Nuclear baseload = the power floor for Physical AI scaling. BWXT is the sole US supplier of naval reactor components (moat) and is expanding into commercial SMR + civilian reactor manufacturing as AI-driven power demand accelerates.

Nuclear baseload is the power floor for Physical AI scaling. BWXT is the component/fuel/microreactor supplier — the "picks-and-shovels" of nuclear — not a reactor brand. The BANR Janus win converts the SMR optionality (previously an open question in the 07-26 note) into an Army program-of-record-adjacent position backed by BWXT's own TRISO fuel fabrication.

• Q1 2026: revenues $860.2M, Adj. EBITDA $148M (+14%), FCF $50.1M (Q1 vs $17.3M prior year = +190%) [SEC 8-K EX-99.1 2026-05-04]
• PCG acquisition (Precision Components Group) = first step establishing US commercial nuclear component manufacturing footprint [8-K 2026-05-04]
• Guidance raised: Adj. EBITDA $650M–$665M, non-GAAP EPS $4.60–$4.75 for FY26 [8-K 2026-05-04]
• Transcript: "Investment in global nuclear markets is accelerating and demand for BWXT's innovative nuclear solutions is growing rapidly" — CEO Geveden Q1 2026 [SEC 8-K]
• TRISO fuel Antares Mark-O first criticality achieved June 2026 — validation of next-gen nuclear fuel program [vault log 2026-06-10]

• technical_scarcity: 8/10 — Sole-source naval reactor manufacturer (bypass impossible, classified, decades of qualification); only major U.S. commercial TRISO fuel fabricator. Trimmed from the prior 9 because the commercial microreactor field is competitive (Army downselected 5 vendors), so the AI-market scarcity is diluted even though the defense scarcity is absolute.
• economic_capture: 6/10 — Profitable and margin-real: Gov Ops adj. EBITDA margin 21.0%, consolidated 17.2%. But the AI/hyperscaler economics are pre-revenue (BANR ops early 2030s); capture today is defense + commercial nuclear components, not the AI bottleneck.
• time_to_monetize: 6/10 — Near-term monetization is real (PCG ramp H2-2026, Commercial Ops +72% YoY, raised guidance, $800M medical sale proceeds by end-2026), but the headline SMR/AI catalyst (BANR ops) is early 2030s — outside the 6–24 month window.

• bypass_test_score 2 — Naval nuclear is a true sole-source (bypass=3) but that moat is defense-scoped, not AI-relevant. In the AI/energy market the buyer can bypass BWXT: 5 microreactor vendors + competing SMR suppliers (Oklo, Kairos, X-energy, NuScale, GE Vernova, Westinghouse).
• concentration_test_score 1 — A reactor/component is one element of a submarine or data-center cost stack, not a dominant share of the buyer's total input.
• hyperscaler_exposure_score 2 — No direct hyperscaler revenue today; exposure is the nuclear-for-AI theme (BANR/Tata LOI interest), not booked revenue.